Your shopping cart is currently empty

NSC 224249 is an effective dual inhibitor of human CYP17A1 and 5α-reductase that effectively blocks the androgen synthesis pathway. It can be used to treat androgen-dependent diseases such as prostate cancer and for research into the regulation of steroid hormone metabolism.


| Description | NSC 224249 is an effective dual inhibitor of human CYP17A1 and 5α-reductase that effectively blocks the androgen synthesis pathway. It can be used to treat androgen-dependent diseases such as prostate cancer and for research into the regulation of steroid hormone metabolism. |
| In vitro | NSC 224249 potently and competitively inhibits CYP17 in human testicular microsomes (IC50 = 1.2 μM for 17α-hydroxylase; 0.6 μM for C17,20-lyase), effectively blocking steroid hormone precursor synthesis [1]. |
| Molecular Weight | 371.51 |
| Formula | C23H33NO3 |
| Cas No. | 2174-13-2 |
| Smiles | C[C@@]12[C@@]3([C@]([C@]4([C@](C)(CC3)C(C(=NO)C)=CC4)[H])(CC=C1C[C@@H](OC(C)=O)CC2)[H])[H] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.